CompletedNot Applicable

Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori

South Korea112 participantsStarted 2012-06

Plain-language summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with H. pylori associated peptic ulcer in scar stage, OR
✓. Non-ulcer dyspepsia patients with H. pylori infection

Exclusion criteria

✕. Under 18 years, OR
✕. Patients with a history of previous treatment of H. pylori infection, OR
✕. Pregnant or Breast feeding women, OR
✕. Patients with severe renal, liver, or heart disease, OR
✕. Patients with gastric malignancy, OR
✕. Patients with a history of drug allergy or hypersensitivity, OR
✕. Patients who had received treatment with antibiotics or proton pump inhibitors, H2 Blocker, Bismuth preparation, Anticoagulant, Ketoconazole, Glucocorticoid during the 2 weeks preceding endoscopy

What they're measuring

Eradication rate

Timeframe: 4 weeks

Trial details

NCT IDNCT01645761

SponsorChuncheon Sacred Heart Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-08

View on ClinicalTrials.gov More Gastric Ulcer Associated With Helicobacter Pylori trials